CJC-1295 (No Dac) 50 mg Monthly subscription

Original price was: $500.00.Current price is: $400.00. / month

Compound: Modified GRF 1-29 (CJC-1295 without Drug Affinity Complex)

Concentration: 5 mg per vial with 10 vials total (50 mg)

Format: Lyophilized White Powder (Strictly for In-Vitro Laboratory Use)

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Syr-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Sark-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-L-Ser-Arg-NH2

Chemical Classification: Growth Hormone Releasing Hormone (GHRH) Analog

Chemical Profile: CJC-1295 (No Dac), frequently referred to in literature as Mod GRF 1-29, is a tetrasubstituted analogue of the endogenous Growth Hormone Releasing Hormone (GHRH). Unlike the standard CJC-1295 (which contains a Drug Affinity Complex for extended half-life), this “No Dac” version retains a short half-life of approximately 30 minutes. This pharmacokinetic profile allows researchers to mimic the body’s natural, physiological pulsatile secretion of growth hormone. By binding to the GHRH receptor on the anterior pituitary, it initiates a release of growth hormone that preserves the natural negative feedback loops, preventing the saturation of receptors often seen with long-acting analogs.

Hypertrophy & Protein Synthesis Models Research utilizes Mod GRF 1-29 to investigate the GHRH-GH-IGF-1 axis. In animal models, the administration of this peptide has been observed to increase plasma Growth Hormone (GH) levels, which subsequently stimulates the liver to secrete Insulin-Like Growth Factor 1 (IGF-1). This cascade is the primary subject of study regarding muscle protein synthesis, nitrogen retention, and cellular hyperplasia in muscle tissue.
Lipolysis & Metabolic Efficiency Scientific studies focus on the role of pulsatile GH release in lipid metabolism. CJC-1295 (No Dac) is utilized to observe the upregulation of lipolysis (the breakdown of triglycerides into free fatty acids) and the oxidation of adipose tissue. Researchers utilize this compound to analyze how GHRH analogs influence metabolic rate and energy expenditure without the side effects of direct pituitary overstimulation.
Slow-Wave Sleep (SWS) Architecture Endogenous GHRH plays a critical role in sleep regulation. CJC-1295 (No Dac) is frequently used in neurological research to study sleep architecture, specifically the promotion of Slow-Wave Sleep (Deep Sleep). Studies aim to understand the correlation between GHRH receptor activation and the consolidation of delta-wave activity, which is linked to cognitive recovery and physical restoration.
Immune System Modulation The GHRH receptor is expressed on various immune cells, including lymphocytes. Research suggests that CJC-1295 (No Dac) may influence thymic function and T-cell proliferation. It serves as a vital tool for immunologists studying the neuroendocrine-immune interface and the potential for peptide-mediated immune system support in aging models.
Bone Mineral Density Similar to other GHRH analogs, CJC-1295 (No Dac) is investigated for its potential effects on skeletal integrity. Preclinical data indicates that sustained (yet pulsatile) elevation of GH and IGF-1 may enhance osteoblast activity and collagen production, offering insights into therapeutic avenues for bone density preservation.

Disclaimer: This product is sold explicitly as a chemical reagent for laboratory research and testing purposes only. It is not intended for human consumption, diagnostic, or therapeutic use. Bodily introduction of any kind into humans or animals is strictly forbidden by law.